Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting… Read More
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address… Read More
Asahi Kasei Pharma aims to expand and enrich the lives of people around the world through the research and development of new drugs and pharmaceutical technologies. To achieve these goals,… Read More
Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading… Read More
15% Discount Available for LSBC Members. Email membership@lifesciencesbc.ca to get a promo code. Where the Rubber Hits the Road: Implementing Innovation and Access for Patients Where we’ll embrace change, turn… Read More
